About BCU CME Meetings Special Editions Meet The Professors Patterns of Care Conference Partnerships Patient Projects Other Tumor Types About us
You are here: Home: BCU 4 | 2008: Matthew J Ellis, MB, BChir, PhD - Select Publications

Select Publications

Ellis MJ et al. A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling. Proc ASCO 2008;Abstract 502.

Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: The P024 trial. Breast Cancer Res Treat 2007;105 Suppl 1:33-43. Abstract

Gissel T et al. Intake of vitamin D and risk of breast cancer-A meta-analysis. J Steroid Biochem Mol Biol 2008 Jun 11. [Epub ahead of print]. Abstract

Goodwin PJ et al. Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 BC. Proc ASCO 2008;Abstract 511.

Goss PE et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97(17):1262-71. Abstract

Gray RG et al. aTTom (adjuvant Tamoxifen — To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive
(ER+) or ER untested breast cancer — Preliminary results. Proc ASCO 2008;Abstract 513.

Ingraham BA et al. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 2008;24(1):139-49. Abstract

Miles D et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc ASCO 2008;Abstract LBA1011.

Miller K et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76. Abstract

O’Shaughnessy J et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.

Parker J et al. A supervised risk predictor of breast cancer based on biological subtypes. Proc ASCO 2008;Abstract 11008.

 

 

 

 

 

 

 

 

 

 

Table of Contents Top of Page

BCU Think Tank

CME Test Online

Home · Search

EDITOR'S NOTE
Austrian tag team
Neil Love, MD
- Select publications

INTERVIEWS
Michael Gnant, MD
- Select publications

Hyman B Muss, MD
- Select publications

Matthew J Ellis, MB, BChir, PhD
- Select publications

Charles L Vogel, MD (Fellows Rounds)
- Select publications

 

Breast Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office

Media Center
PDF
Media Center
Podcast
Previous Editions
Home Terms and Conditions of Use and General Disclaimer | Privacy Policy
Copyright © 2008 Research To Practice. All Rights Reserved